Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India
Background and Objectives: Vaccination being the only way to reduce mortality from the dreaded COVID-19 disease, the vaccine was introduced in India as per the advice of the National Expert Group on January 16, 2021. Duration of immune response elicited by the vaccines has always been a matter of c...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2022-10-01
|
| Series: | Iranian Journal of Microbiology |
| Subjects: | |
| Online Access: | https://ijm.tums.ac.ir/index.php/ijm/article/view/3697 |
| _version_ | 1811250653344825344 |
|---|---|
| author | Partha Sarathi Satpathi Sayantani Endow Kripasindhu Gantait Pearl Helena Chand Abhishek Jaiswal Biswajit Jana Panchanan Kundu Tarapada Ghosh |
| author_facet | Partha Sarathi Satpathi Sayantani Endow Kripasindhu Gantait Pearl Helena Chand Abhishek Jaiswal Biswajit Jana Panchanan Kundu Tarapada Ghosh |
| author_sort | Partha Sarathi Satpathi |
| collection | DOAJ |
| description |
Background and Objectives: Vaccination being the only way to reduce mortality from the dreaded COVID-19 disease, the vaccine was introduced in India as per the advice of the National Expert Group on January 16, 2021. Duration of immune response elicited by the vaccines has always been a matter of content. With new variants emerging every other day, the study was done to look for the antibody response in vaccine recipients post second dose of vaccination.
Materials and Methods: A longitudinal observational study was conducted from August 2021 to February 2022 in fully vaccinated individuals who took either Covishield (AZD1222) or Covaxin (BBV-152). Blood was collected from the individuals at 12-16 weeks post-vaccination to look for IgG antibody response against S1 spike protein of SARS-CoV2 by ELISA. Follow-up was done at 32 weeks post the second dose in individuals who had received Covishield.
Results: Among 176 individuals, IgG antibody against S1 spike protein was found to be positive in 89.7% (158). Covishield recipients showed higher antibody response (99.1%) as compared to Covaxin recipients (71%). Antibody response was higher in males, individuals less than 50 years, and non-comorbid individuals. Of 38 Covishield recipients, IgG antibody response was positive in 28 (73.6%) individuals when followed up at 32 weeks post the second vaccination dose.
Conclusion: The study gives us input with regard to the long-term antibody kinetics of both vaccines. The study has a follow-up plan to co-relate the antibody response to the neutralization test.
|
| first_indexed | 2024-04-12T16:07:53Z |
| format | Article |
| id | doaj.art-4298a513617148e0bc958d4bedd9ce5f |
| institution | Directory Open Access Journal |
| issn | 2008-3289 2008-4447 |
| language | English |
| last_indexed | 2024-04-12T16:07:53Z |
| publishDate | 2022-10-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Microbiology |
| spelling | doaj.art-4298a513617148e0bc958d4bedd9ce5f2022-12-22T03:25:59ZengTehran University of Medical SciencesIranian Journal of Microbiology2008-32892008-44472022-10-01145Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, IndiaPartha Sarathi Satpathi0Sayantani Endow1Kripasindhu Gantait2Pearl Helena Chand3Abhishek Jaiswal4Biswajit Jana5Panchanan Kundu6Tarapada Ghosh7Department of Microbiology, Midnapore Medical College and Hospital, West Bengal, IndiaDepartment of Microbiology, Midnapore Medical College and Hospital, West Bengal, IndiaDepartment of Medicine, Midnapore Medical College and Hospital, West Bengal, IndiaDepartment of Microbiology, Midnapore Medical College and Hospital, West Bengal, IndiaDepartment of Microbiology, Midnapore Medical College and Hospital, West Bengal, IndiaDepartment of Microbiology, Midnapore Medical College and Hospital, West Bengal, IndiaDepartment of Anatomy, Midnapore Medical College and Hospital, West Bengal, IndiaDepartment of Pediatrics, Midnapore Medical College and Hospital, West Bengal, India Background and Objectives: Vaccination being the only way to reduce mortality from the dreaded COVID-19 disease, the vaccine was introduced in India as per the advice of the National Expert Group on January 16, 2021. Duration of immune response elicited by the vaccines has always been a matter of content. With new variants emerging every other day, the study was done to look for the antibody response in vaccine recipients post second dose of vaccination. Materials and Methods: A longitudinal observational study was conducted from August 2021 to February 2022 in fully vaccinated individuals who took either Covishield (AZD1222) or Covaxin (BBV-152). Blood was collected from the individuals at 12-16 weeks post-vaccination to look for IgG antibody response against S1 spike protein of SARS-CoV2 by ELISA. Follow-up was done at 32 weeks post the second dose in individuals who had received Covishield. Results: Among 176 individuals, IgG antibody against S1 spike protein was found to be positive in 89.7% (158). Covishield recipients showed higher antibody response (99.1%) as compared to Covaxin recipients (71%). Antibody response was higher in males, individuals less than 50 years, and non-comorbid individuals. Of 38 Covishield recipients, IgG antibody response was positive in 28 (73.6%) individuals when followed up at 32 weeks post the second vaccination dose. Conclusion: The study gives us input with regard to the long-term antibody kinetics of both vaccines. The study has a follow-up plan to co-relate the antibody response to the neutralization test. https://ijm.tums.ac.ir/index.php/ijm/article/view/3697Immunoglobulin G;Vaccination;India;Spike glycoprotein |
| spellingShingle | Partha Sarathi Satpathi Sayantani Endow Kripasindhu Gantait Pearl Helena Chand Abhishek Jaiswal Biswajit Jana Panchanan Kundu Tarapada Ghosh Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India Iranian Journal of Microbiology Immunoglobulin G; Vaccination; India; Spike glycoprotein |
| title | Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India |
| title_full | Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India |
| title_fullStr | Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India |
| title_full_unstemmed | Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India |
| title_short | Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India |
| title_sort | anti sars cov 2 igg antibody response in fully vaccinated covishield azd1222 and covaxin bbv 152 recipients a study done in southern part of west bengal india |
| topic | Immunoglobulin G; Vaccination; India; Spike glycoprotein |
| url | https://ijm.tums.ac.ir/index.php/ijm/article/view/3697 |
| work_keys_str_mv | AT parthasarathisatpathi antisarscov2iggantibodyresponseinfullyvaccinatedcovishieldazd1222andcovaxinbbv152recipientsastudydoneinsouthernpartofwestbengalindia AT sayantaniendow antisarscov2iggantibodyresponseinfullyvaccinatedcovishieldazd1222andcovaxinbbv152recipientsastudydoneinsouthernpartofwestbengalindia AT kripasindhugantait antisarscov2iggantibodyresponseinfullyvaccinatedcovishieldazd1222andcovaxinbbv152recipientsastudydoneinsouthernpartofwestbengalindia AT pearlhelenachand antisarscov2iggantibodyresponseinfullyvaccinatedcovishieldazd1222andcovaxinbbv152recipientsastudydoneinsouthernpartofwestbengalindia AT abhishekjaiswal antisarscov2iggantibodyresponseinfullyvaccinatedcovishieldazd1222andcovaxinbbv152recipientsastudydoneinsouthernpartofwestbengalindia AT biswajitjana antisarscov2iggantibodyresponseinfullyvaccinatedcovishieldazd1222andcovaxinbbv152recipientsastudydoneinsouthernpartofwestbengalindia AT panchanankundu antisarscov2iggantibodyresponseinfullyvaccinatedcovishieldazd1222andcovaxinbbv152recipientsastudydoneinsouthernpartofwestbengalindia AT tarapadaghosh antisarscov2iggantibodyresponseinfullyvaccinatedcovishieldazd1222andcovaxinbbv152recipientsastudydoneinsouthernpartofwestbengalindia |